They are called Ascophyllum nodosum e Vesicular fucuss the two marine algae which, based on the results of a clinical study in which approximately 500 patients participated, appear to contribute to reducing the cardiovascular risk linked to metabolic syndrome, thanks to the positive effects on body weight, blood sugar, blood pressure and lipid profile . Metabolic syndrome is in fact characterized by a complex clinical picture, due to the simultaneous presence of diabetes, high blood pressure and obesity.
The metabolic syndrome
Each of these different conditions constitutes a risk factor for the cardiovascular system. In fact, metabolic syndrome is often associated with blood clotting problems (such as the formation of thrombi and emboli) and a state of chronic inflammation of the body. Globally, it is estimated that it affects around one in four adults and is increasingly widespread globally, as we recall Antonio Nicolucci, director of the Center for Outcomes Research and Clinical Epidemiology (Coresearch). Genetic factors, but above all unhealthy lifestyles, may contribute to its onset. In fact, an incorrect diet plays a crucial role in this context, as does poor physical activity, “which in Italy alone affects 36% of the population”, says Nicolucci. And he continues: “It is clear that we need to intervene on these very dangerous behaviors for public health. At the same time, however, it is essential to be able to resort to effective therapies.”
Nutraceuticals to support good habits
Help also seems to come from nutraceuticals: in particular from a product based on two algae originating from the Atlantic Ocean, the Ascophyllum nodosum and the Vesicular inkto which chromium picolinate is added: “In one clinical study on over 500 patients it has been demonstrated that the Gdue supplement, after six months of use, can reduce cardiovascular risk by 27% thanks to the positive effects on body weight, blood sugar, blood pressure and lipid profile. Even fasting blood insulin levels, which are altered in those with metabolic syndrome, are improved.” Treatment with Gdue – concludes Nicolucci – is generally well tolerated: mild and transient gastro-intestinal side effects have been reported in less than 3% of treated patients”.
Subjects